Cargando…

Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours

BACKGROUND: Microsatellite instability (MSI) is a molecular phenotype due to defective DNA mismatch repair (MMR) system. It is used to predict outcome of colorectal tumours and to screen tumours for Lynch syndrome (LS). A pentaplex panel composed of five mononucleotide markers has been largely recom...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagin, A, Zerimech, F, Leclerc, J, Wacrenier, A, Lejeune, S, Descarpentries, C, Escande, F, Porchet, N, Buisine, M-P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670492/
https://www.ncbi.nlm.nih.gov/pubmed/23652311
http://dx.doi.org/10.1038/bjc.2013.213
_version_ 1782271857722916864
author Pagin, A
Zerimech, F
Leclerc, J
Wacrenier, A
Lejeune, S
Descarpentries, C
Escande, F
Porchet, N
Buisine, M-P
author_facet Pagin, A
Zerimech, F
Leclerc, J
Wacrenier, A
Lejeune, S
Descarpentries, C
Escande, F
Porchet, N
Buisine, M-P
author_sort Pagin, A
collection PubMed
description BACKGROUND: Microsatellite instability (MSI) is a molecular phenotype due to defective DNA mismatch repair (MMR) system. It is used to predict outcome of colorectal tumours and to screen tumours for Lynch syndrome (LS). A pentaplex panel composed of five mononucleotide markers has been largely recommended for determination of the MSI status. However, its sensitivity may be taken in default in occasional situations. The aim of the study was to optimise this panel for the detection of MSI. METHODS: We developed an assay allowing co-amplification of six mononucleotide repeat markers (BAT25, BAT26, BAT40, NR21, NR22, NR27) and one polymorphic dinucleotide marker (D3S1260) in a single reaction. Performances of the new panel were evaluated on a cohort of patients suspected of LS. RESULTS: We demonstrate that our assay is technically as easy to use as the pentaplex assay. The hexaplex panel shows similar performances for the identification of colorectal and non-MSH6-deficient tumours. On the other hand, the hexaplex panel has higher sensitivity for the identification of MSH6-deficient tumours (94.7% vs 84.2%) and MMR-deficient tumours other than colorectal cancer (92.9% vs 85.7%). CONCLUSION: The hexaplex panel could thus be an attractive alternative to the pentaplex panel for the identification of patients with LS.
format Online
Article
Text
id pubmed-3670492
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36704922014-05-28 Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours Pagin, A Zerimech, F Leclerc, J Wacrenier, A Lejeune, S Descarpentries, C Escande, F Porchet, N Buisine, M-P Br J Cancer Molecular Diagnostics BACKGROUND: Microsatellite instability (MSI) is a molecular phenotype due to defective DNA mismatch repair (MMR) system. It is used to predict outcome of colorectal tumours and to screen tumours for Lynch syndrome (LS). A pentaplex panel composed of five mononucleotide markers has been largely recommended for determination of the MSI status. However, its sensitivity may be taken in default in occasional situations. The aim of the study was to optimise this panel for the detection of MSI. METHODS: We developed an assay allowing co-amplification of six mononucleotide repeat markers (BAT25, BAT26, BAT40, NR21, NR22, NR27) and one polymorphic dinucleotide marker (D3S1260) in a single reaction. Performances of the new panel were evaluated on a cohort of patients suspected of LS. RESULTS: We demonstrate that our assay is technically as easy to use as the pentaplex assay. The hexaplex panel shows similar performances for the identification of colorectal and non-MSH6-deficient tumours. On the other hand, the hexaplex panel has higher sensitivity for the identification of MSH6-deficient tumours (94.7% vs 84.2%) and MMR-deficient tumours other than colorectal cancer (92.9% vs 85.7%). CONCLUSION: The hexaplex panel could thus be an attractive alternative to the pentaplex panel for the identification of patients with LS. Nature Publishing Group 2013-05-28 2013-05-07 /pmc/articles/PMC3670492/ /pubmed/23652311 http://dx.doi.org/10.1038/bjc.2013.213 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Pagin, A
Zerimech, F
Leclerc, J
Wacrenier, A
Lejeune, S
Descarpentries, C
Escande, F
Porchet, N
Buisine, M-P
Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
title Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
title_full Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
title_fullStr Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
title_full_unstemmed Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
title_short Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
title_sort evaluation of a new panel of six mononucleotide repeat markers for the detection of dna mismatch repair-deficient tumours
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670492/
https://www.ncbi.nlm.nih.gov/pubmed/23652311
http://dx.doi.org/10.1038/bjc.2013.213
work_keys_str_mv AT pagina evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT zerimechf evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT leclercj evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT wacreniera evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT lejeunes evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT descarpentriesc evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT escandef evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT porchetn evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours
AT buisinemp evaluationofanewpanelofsixmononucleotiderepeatmarkersforthedetectionofdnamismatchrepairdeficienttumours